Recently, scientists at the biopharmaceutical company CanBas have disclosed CBS9106, an orally-active synthetic small molecule which reversibly prevents CRM1-mediated nuclear export and is currently being developed as an anti-cancer agent in preclinical trials [136] although the mechanism of its reversible binding remains to be elucidated [137]. This evidence concerns the gene XPO1 and cancer.